PET imaging of bone metastases with FDG, fluoride and gallium-somatostatin analogs

Einat Even Sapir Weizer

doi:10.1007/978-88-470-5292-5_30

PET imaging of bone metastases with FDG, fluoride and gallium-somatostatin analogs

Einat Even Sapir Weizer^*

^*Corresponding author for this work

Diagnostic Imaging

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Imaging is aimed at identifying skeletal involvement as early as possible, to determine the extent of skeletal disease, to evaluate the presence of complications, to monitor response to therapy, and occasionally to guide biopsy. Detection of bone metastases in nuclear medicine is based on either direct visualization of tumor cells using radiotracers that accumulate in these cells, or tracers, the uptake of which reflects bone reaction secondary to the presence of malignant cells. The following summary describes the role of positron emission tomography-computed tomography (PET-CT) in assessment of bone metastases using three different PET tracers: ¹⁸F-fluo-rdeoxyglucose (¹⁸F-FDG), which directly accumulates in tumor cells of FDG-avid malignancies; ⁶⁸Ga-somato-statin, which accumulates in neuroendocrine tumors that show high expression of somatostatin receptors; and ¹⁸F-fluoride, a bone-seeking agent that reflects secondary bone reactive changes.

Original language	English
Title of host publication	Musculoskeletal Diseases 2013-2016
Subtitle of host publication	Diagnostic Imaging and Interventional Techniques
Publisher	Springer-Verlag Milan
Pages	226-228
Number of pages	3
ISBN (Electronic)	9788847052925
ISBN (Print)	9788847052918
DOIs	https://doi.org/10.1007/978-88-470-5292-5_30
State	Published - 1 Jan 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-88-470-5292-5_30

Cite this

@inbook{d52ab4428c1c430b864a756baa1f8e1c,

title = "PET imaging of bone metastases with FDG, fluoride and gallium-somatostatin analogs",

abstract = "Imaging is aimed at identifying skeletal involvement as early as possible, to determine the extent of skeletal disease, to evaluate the presence of complications, to monitor response to therapy, and occasionally to guide biopsy. Detection of bone metastases in nuclear medicine is based on either direct visualization of tumor cells using radiotracers that accumulate in these cells, or tracers, the uptake of which reflects bone reaction secondary to the presence of malignant cells. The following summary describes the role of positron emission tomography-computed tomography (PET-CT) in assessment of bone metastases using three different PET tracers: 18F-fluo-rdeoxyglucose (18F-FDG), which directly accumulates in tumor cells of FDG-avid malignancies; 68Ga-somato-statin, which accumulates in neuroendocrine tumors that show high expression of somatostatin receptors; and 18F-fluoride, a bone-seeking agent that reflects secondary bone reactive changes.",

author = "Weizer, \{Einat Even Sapir\}",

note = "Publisher Copyright: {\textcopyright} Springer-Verlag Italia 2013.",

year = "2013",

month = jan,

day = "1",

doi = "10.1007/978-88-470-5292-5\_30",

language = "אנגלית",

isbn = "9788847052918",

pages = "226--228",

booktitle = "Musculoskeletal Diseases 2013-2016",

publisher = "Springer-Verlag Milan",

}

TY - CHAP

T1 - PET imaging of bone metastases with FDG, fluoride and gallium-somatostatin analogs

AU - Weizer, Einat Even Sapir

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Imaging is aimed at identifying skeletal involvement as early as possible, to determine the extent of skeletal disease, to evaluate the presence of complications, to monitor response to therapy, and occasionally to guide biopsy. Detection of bone metastases in nuclear medicine is based on either direct visualization of tumor cells using radiotracers that accumulate in these cells, or tracers, the uptake of which reflects bone reaction secondary to the presence of malignant cells. The following summary describes the role of positron emission tomography-computed tomography (PET-CT) in assessment of bone metastases using three different PET tracers: 18F-fluo-rdeoxyglucose (18F-FDG), which directly accumulates in tumor cells of FDG-avid malignancies; 68Ga-somato-statin, which accumulates in neuroendocrine tumors that show high expression of somatostatin receptors; and 18F-fluoride, a bone-seeking agent that reflects secondary bone reactive changes.

AB - Imaging is aimed at identifying skeletal involvement as early as possible, to determine the extent of skeletal disease, to evaluate the presence of complications, to monitor response to therapy, and occasionally to guide biopsy. Detection of bone metastases in nuclear medicine is based on either direct visualization of tumor cells using radiotracers that accumulate in these cells, or tracers, the uptake of which reflects bone reaction secondary to the presence of malignant cells. The following summary describes the role of positron emission tomography-computed tomography (PET-CT) in assessment of bone metastases using three different PET tracers: 18F-fluo-rdeoxyglucose (18F-FDG), which directly accumulates in tumor cells of FDG-avid malignancies; 68Ga-somato-statin, which accumulates in neuroendocrine tumors that show high expression of somatostatin receptors; and 18F-fluoride, a bone-seeking agent that reflects secondary bone reactive changes.

UR - https://www.scopus.com/pages/publications/84955708787

U2 - 10.1007/978-88-470-5292-5_30

DO - 10.1007/978-88-470-5292-5_30

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:84955708787

SN - 9788847052918

SP - 226

EP - 228

BT - Musculoskeletal Diseases 2013-2016

PB - Springer-Verlag Milan

ER -

PET imaging of bone metastases with FDG, fluoride and gallium-somatostatin analogs

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this